Tweets
AA race strongest predictor of CVD risk in SLE with event risk peaking 1-2 years post dx. With this information, we need to better address this to protect our patients. https://t.co/feA4bcvuU2 Plenary abs #805 #ACR19 @RheumNow https://t.co/OdK5XvrpeJ
Dr. Rachel Tate @uptoTate ( View Tweet )
6 years 9 months ago
Patients self-rate opiates as most effective for #fibromyalgia
Gabapentin least effective
Abstract 0242 #ACR19 @RheumNow @samwhittle https://t.co/EoRTMJ6PI1
Philip Robinson @philipcrobinson ( View Tweet )
6 years 9 months ago
Following RITAZAREM, would you use rituximab maintenance for ANCA-associated vasculitis patients (cost aside)? @RheumNow
David Liew @drdavidliew ( View Tweet )
6 years 9 months ago
#ACR19 @rheumnow Abstr #0301
@PanlarLeague Ultrasound Study Group Recommendations for Imaging in #Gout
“...1st evidence-based & expert opinion recs for use of imaging in pts w gout, providing some guidelines for their use in daily clinical practice”
8 recs for imaging in gout: https://t.co/WLSrzxLKUH
Adam Kilian MD @KilianMD ( View Tweet )
6 years 9 months ago
One thing that really impressed me from RITAZAREM (ritux vs azathioprine maintenance following ritux induction in AAV) apart from fewer relapses with ritux, is how well it was tolerated. Not even a hypogammaglob signal! #ACR19 ABST0806 @RheumNow https://t.co/9l1jqlX0jg
David Liew @drdavidliew ( View Tweet )
6 years 9 months ago
RITAZAREM Trial
Fixed interval 4 monthly repeat dose Rituximab vs Aza for maintenance
Pop: AAV at relapse, given 375mg/m2
Rituximab seemed superior
#ACR19 @rheumnow
More details Abst0806
Dr Irwin Lim @_connectedcare ( View Tweet )
6 years 9 months ago
EMA has approved the subcutaneous version of CT-P13 an infliximab biosimilar based on this trial by Rene Westhovens. Equal efficacy of IV and SC CT-P13 with great maintenance on SC form. Interestingly high trough levels with SC CT-P13. #ACR19 @RheumNow Abst 807 https://t.co/hfrtJRMPdt
Dr. John Cush @RheumNow ( View Tweet )
6 years 9 months ago
In you #SLE pts how do you routinely assess CV risk
Dr. John Cush @RheumNow ( View Tweet )
6 years 9 months ago
Great data on reducing low benefit care in rheum pathology ordering. Reducing dsDNA requests in patients with a negative ANA #ACR19 @RheumNow Abstract 0265 https://t.co/b5gWwPi487
Philip Robinson @philipcrobinson ( View Tweet )
6 years 9 months ago
RheumNow’s expanded coverage of the #ACR2019 annual meeting is sponsored in part by Sanofi Genzyme and Regeneron. All content chosen by RheumNow and its faculty.
Dr. John Cush @RheumNow ( View Tweet )
6 years 9 months ago
Abstract 0348 #gout Details of the changes over time in gout medications in US RISE database.
Allopurinol and pegloticase slowly grinding higher… Lesinurad increased significantly in comparison
@RheumNow #ACR19 https://t.co/VcqNtB2eXN
Philip Robinson @philipcrobinson ( View Tweet )
6 years 9 months ago
CVS risk in black patients with SLE (retro cohort)
18x higher in early SLE & over long-term, 6x
Highest risk at 1 and 10yrs after SLE diagnosis
Discoid rash 3x assoc with CVD
#ACR19 @rheumnow Abst0805
Dr Irwin Lim @_connectedcare ( View Tweet )
6 years 9 months ago
Holy smokes! 18x higher risk of cardiovascular disease in Black SLE patients, highest at 1 and 10 years after diagnosis - Dr Shivani Garg #ACR19 @rheumnow #Abstr #ACRBest https://t.co/kXoMNu4QKb
Jonathan Hausmann MD @hausmannMD ( View Tweet )
6 years 9 months ago
Pneumococcal vaccine recommendations for pts with AID are confusing and data is C level - but we still recommend prime/boost administration of PCV13 followed by PPSV23 @RheumNow @LCalabreseDO @BetsyKirch #ACR19 #cleclinicrheum https://t.co/WFBjQRRgmb
Cassandra Calabrese @CCalabreseDO ( View Tweet )
6 years 9 months ago
Plenary session shows AA/blacks at higher risk for #SLE & that blacks have 16 fold increased risk for IHD, CVD. CV risk accelerated at yrs 1 & 10. Copy & paste. #ACR19 @RheumNow Abst 805 #ACRBest https://t.co/kgfwjd1XOc
Dr. John Cush @RheumNow ( View Tweet )
6 years 9 months ago
